in Newswire February 22, 2019

Amgen, Teva Sued Over Allegedly Anticompetitive Practices Relating to Sensipar Pricing

by Erin Shaak

Last Updated on February 22, 2019

Ufcw Local 1500 Welfare Fund v. Amgen Inc. et al

Filed: February 21, 2019 § 1:19cv369

Amgen Inc., Teva Pharmaceuticals USA, Inc. and three Teva subsidiaries have been named in a proposed class action in which they’re accused of entering into an unlawful, anticompetitive agreement that led consumers to pay inflated prices for Sensipar.

Last Updated on February 22, 2019 — 4:02 PM

Erin Shaak

Erin works primarily on’s newswire, reporting on cases as they happen.

About is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.